Nanotechnology Platforms for Cancer Therapy: from Bench to Bedside
Senior Director, Research
Scott manages Cerulean?s diverse research team of formulation scientists, synthetic chemists and biologists. Prior to joining Cerulean, Scott was the Director of the Chemical Biology Platform at the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT), directing a multi-disciplinary team of professional scientists and technicians in the fields of synthetic chemistry, analytical chemistry, high-throughput screening, computational science and software engineering. This interdisciplinary organization is closely affiliated with the laboratory of Stuart Schreiber from Harvard University and is one of the largest and oldest academic screening centers in the country. Prior to joining the Broad Institute, Scott worked at Millennium Pharmaceuticals, where he managed scientific teams in cell biology, molecular biology, neuroscience and bioinformatics for a large-scale genomics-based drug discovery program. Earlier in his career, Scott was at Neurocrine Biosciences, where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders.
Scott received his B.S. from MIT in electrical engineering, Ph.D. from the University of California at Berkeley in neuroscience, and completed his postdoctoral fellowship at the Vollum Institute in Portland, Oregon.